hi esc, i found this for relenza;
" RESULTS: The proportion of families with at least one initially healthy household contact in whom influenza developed was smaller in the zanamivir group than in the placebo group (4 percent vs. 19 percent, P<0.001); the difference represented a 79 percent reduction in the proportion of families with at least one affected contact."
Relenza: 4% vs 19% placebo = 79% difference
Inavir: x% vs 8.5% placebo = 43% difference, where x = 3.6%
so, if we used the relenza's placebo result of 19%, the difference would be 81%
- Forums
- ASX - By Stock
- BTA
- Ann: Phase III prophylaxis trial for CS-8958
Ann: Phase III prophylaxis trial for CS-8958 , page-33
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online